Abstract

Treatment of COVID-19 comorbid hypertension involves many drugs with therapeutic risk of non-guidelines and potential drug interactions. Study aimed to determine the demographic characteristics, clinical degree, accuracy of drugs and doses and potential drug interactions. Study design was cross-sectional through retrospective data collection. Samples that meet the criteria obtained 70 samples. The results were 51.4% female sample, the highest age was 46-59 y.o (48.6%), the most degree of COVID-19 was moderate (61.4%), the highest degree of hypertension was grade 1 (48.6%) and the longest length of stay was >14 days (51.4%). The accuracy of COVID-19 therapy were 78.6% accurate drug, 21.4% inaccurate drug, and 100% accurate dose. The accuracy of antihypertensive were 82.9% accurate drug, 17.1% inaccurate drug, 95.7% accurate dose and 4.3% inaccurate dose. Samples with potential drug interactions were 97.1%, the highest number of potential drug interactions was 1-5 events (52.9%), based on severity 60.2% moderate, 20.1% minor, 13.2% major, and 6.5% unknown. Correlation test results sig. (p-value) 0.237. The conclusion showed that most samples were female, aged 46-59, moderate-grade COVID-19 patients with grade 1 hypertension, and length of stay >14 days. There is accuracy or inaccuracy of drugs and doses, potential drug interactions and there is no relationship between length of stay and potential drug interactions.

References

  1. Ministry of Health Indonesia Republic. "Guidelines for prevention and control of coronavirus disease 2019 (COVID-19) revision 5th" Jakarta: Directorate General of Disease Prevention and Control. 1–214 p. 2020.
  2. Task for Handling COVID-19. "Spread map COVID-19" [Internet]. [cited 2022 Jan 2]. Available from: https://covid19.go.id/peta-sebaran-covid19.
  3. District Health Office of Sragen. "Sragen prespective COVID-19" [Internet]. [cited 2022 Jan 2]. Available from: https://corona.sragenkab.go.id/.
  4. Zulkarni, N. Nessa, Y. Athifah. "Analysis of the accuracy of selecting and determining drug regimens in patients with Chronic Obstructive Pulmonary Disease (COPD)". J Sains Farm Klin. vol. 6, no. 2. pp.158. 2019
  5. Ministry of Health Indonesia Republic. "Rational medicine use module in practice". Jakarta: Directorate General of Pharmaceutical Development and Medical Devices. pp. 192. 2011.
  6. I.H. Stockley. "Stockley’s drug interactions". Eight Edition. Baxter K, editor. London: Pharmaceutical Press. 2008.
  7. Syamsudin. "Drug interactions: basic and clinical concepts". Jakarta: Publisher: Universitas Indonesia (UI-Press). 2011.
  8. L.A. Kusumawardani, N. Maria, Y.N. Fanani, "analysis of potential drug interactions in hospitalized patients COVID-19 at hospital in West Java". J Ilm Farm vol. 17, no. 2, 2021
  9. C. Awortwe, I Cascorbi. "Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions'. Pharmacol Res. vol.1, no.11. 2020
  10. S. Wang, Q. Zhang, P. Wang, et al. "Clinical features of hypertensive patients with COVID-19 compared with a normotensive group: Single-center experience in China". Open Med. vol. 16. no. 1, pp.367,74. 2021
  11. Ministry of Health Indonesia Republic. "Basic health research national report 2018". Jakarta: Health Research and Development Agency; p. 628. 2019.
  12. A. Pradhan and P.E. Olsson. "Sex differences in severity and mortality from COVID-19: are males more vulnerable?" Biol Sex Differ. vol. 7, no. 1, pp.11. 2020
  13. N.A. Putri, A.E. Putra, R. Mariko. "Relationship of age, sex and symptoms with incidence
  14. COVID19 at West Sumatera". Maj Kedokt Andalas. 2021;44(2).
  15. X. Xu, X. Wu, X. Jiang, et al. "Clinical findings in a group of patients infected with the 2019 novel coronavirus ( SARS-Cov-2 ) outside of Wuhan , China : retrospective case series. (January):1–7. 2020
  16. J. Leng and D.R. Goldstein. "Impact of aging on viral infections". Microbes Infect. vol. 12. pp. 1120–4. 2011.
  17. F. Oktarina, A. Maria, M. Perangin. "Evaluation of the rationality of using Covid-19 drugs in inpatient care at the Immanuel Hospital in Bandar Lampung in 2020". Journal Mandala Pharmacon Indonesia. vol. 7, no. 2, 2021
  18. B.D. Pepitasari and T.D. Anggraini. "Overview of therapeutic management in confirmed COVID-19 patients at Hospital X Kota Surakarta for the period March – December 2020". Indones J Med Sci. vol. 8, no. 2, pp. 119–26. 2021.
  19. Organizer team. "Guidelines for the Management of COVID-19. Edition 3". Jakarta: Indonesian Association of Pulmonary Doctors Indonesian Association of Cardiovascular Specialists Indonesian, Association of Internal Medicine Specialists Indonesian, Association of Anesthesiologists and Intensive Therapy Indonesian, Association of Pediatricians. 2020.
  20. M.P.R. Sumawa, A.C. Wullur, P.V.Y. Yamlean. "Evaluation of the rationale for the use of antihypertensive drugs in hospitalized hypertensive patients at RSUP Prof. Dr. R. D. Kandou Manado Period January-Juny 2014". Pharmacon. vol. 4, no. 3, pp. 126–33, 2015.
  21. Association of Indonesian Hypertension Physicians. "Hypertension Management Consensus 2019". Jakarta: Association of Indonesian Hypertension Physicians. p. 118. 2019
  22. S.M.Samrah, A.H. Al-Mistarehi, T.Kewan, et al. "Viral clearance course of covid-19 outbreaks". J Multidiscip Healthc. vol. 14. pp. 555–65. 2021
  23. D.L. Ramatillah, S.Isnaini. Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. PLoS One. vol. 16, pp. 1–11, 2021
  24. F.A.Baihaqi, H.Rumaropen. "Factors related to length of stay COVID-19 patient at RSUD Serui Province Papua: Coss-sectional study". J Penyakit Dalam Indonesia. vol. 8, no. 4, pp. 187. 2022
  25. J.T.Widjaja, L.Kwee, A.K.Giantara et al. "Charateristic inpatients COVID-19 at RS Immanuel Bandung, Indonesia". J Med Health. vol. 3, no. 2, pp. 164–75. 2021.
  26. A.P.Setiadi, Y.I.Wibowo, S.V.Halim et al. "Management of Patients with COVID-19: a narrative study". J Farm Klin Indonesia. vol.9, no.1, 2020.
  27. Y. Levani, A.D. Prastya, S. Mawaddatunnadila. "Coronavirus disease 2019 (COVID-19): Pathogenesis, Clinical Manifestations and Therapeutic Selection". J Kedokteran dan Kesehatan. vol. 17, no. 1, pp. 44–57. 2021.
  28. C.A. Michele, B. Angelo, L.Valeria, et al. "Vitamin supplements in the Era of SARS-Cov2 pandemic". GSC Biological and Pharmaceutical Sciences. vol. 11, no. 02, pp. 7–19. 2020
  29. M.W.E Tyashapsari and A. K. Zulkarnain. "Drug Use in Hypertensive patients in the inpatient unit of the central general hospital dr. Kariadi semarang". Maj Farmasetika. vol. 8, no. 2 pp. 150. 2012
  30. E.K.Untari, A.R.Agilina, R.Susanti. "Evaluation of the rationality of using antihypertension drugs at the Siantan Hilir Kota Health Center in Pontianak 2015". Pharm Sci Res. vol. 5, no. 1, pp. 32–9, 2018.
  31. S.D. Astuti, E. Endang. "Study of antihypertensive use and potential for drug interactions in the treatment of hypertensive patients with complications". J Farm Indonesis. vol. 15, no. 2, pp. 148–62. 2018
  32. A.F. Muti, U. Chasanah. "Evaluation of the rationality of using diuretics in hospitalized chronic kidney failure patients in rsud Dr. Saiful Anwar Malang". Sainstech Farma. vol. 9, no. 2, pp. 23–31, 2016
  33. S.S. Maulidia, F. Mahmudah, Y. Sastyarina. "Study of potential drug interactions in Covid-19 patients at Hospital X Samarinda City". Proceeding Mulawarman Pharm Conf. pp. 295–301. 2020
  34. Yuniar, A. Ramadhiani, D. Asyifa, et al. "Potential drug interactions in confirmed COVID-19 patients with comorbidities in the Ogan ward RSUP dr. Mohammad Hoesin Palembang periode april-juni 2021". Maj Farm. vol. 8, no.1, pp. 43–50. 2022
  35. S. Nurhasanah, F. Lestari, S.P. Fitrianingsih. "Antihypertensive drug interaction study on outpatient prescriptions at a health center in West Bandung district". Proceeding Farmasi UNISBA vol. 3, no. 2, 2017.